Letter to the Editor: Akkermansia muciniphila serves as an immunomodulator for type 1 diabetes mellitus: Promises and pitfalls

Abstract

We read with great interest the study by Huang et al published in the recent issue of the World Journal of Diabetes, which presented the potential of Akkermansia muciniphila (A. muciniphila) as an immunomodulator in a murine model of type 1 diabetes mellitus (T1DM). However, several concerns about translating these results into clinical applications warrant attention. Firstly, despite the observed improvements in immune regulation, particularly the enhancement of Tregs and the reduction of pro-inflammatory cytokines, A. muciniphila did not reverse the hyperglycemia or restore insulin production in the mice. This raises questions about the feasibility of using A. muciniphila as a therapeutic agent in advanced stages of T1DM, where β-cell destruction is likely irreversible. Additionally, the specific effect of A. muciniphila on immune pathways in T1DM remains unclear, and the possibility of unforeseen immune responses needs further exploration. While another important consideration is the potential long-term effects of altering gut microbiota composition, as the reduction in Actinobacteria could have broader implications for gut health, which were not fully addressed in the study. Therefore, while the findings are promising, further studies are essential to evaluate the long-term safety and efficacy of A. muciniphila in clinical settings, particularly for individuals with established T1DM.

Keywords: Type 1 diabetes mellitus; Akkermansia muciniphila; Immunomodulator; Gut microbiota; Clinical application

Core Tip: This article offers a critical evaluation of the therapeutic potential of Akkermansia muciniphila in the context of type 1 diabetes mellitus. While the study has yielded promising results in terms of immunomodulatory effects, the absence of metabolic reversal highlights significant challenges in translating these findings into clinical applications. This article emphasizes the need for caution regarding the inhibition of immune pathways, interspecies variability, and potential ecological trade-offs within the gut microbiome. Future investigations should prioritize clinical trials and combination therapies to realize its therapeutic potential in type 1 diabetes mellitus.